López-Vilella R, Sanz-Sánchez J, Sánchez-Lázaro I, Marques-Sule E, Rueda-Soriano J, Almenar-Bonet L
Heart Failure and Transplantation Unit, Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Physiotherapy Department, University of Valencia, Valencia, Spain.
Int J Organ Transplant Med. 2018;9(2):97-100. Epub 2018 May 1.
Direct oral anticoagulants have suggested a favorable profile compared with vitamin K antagonists. However, the lack of treatment to reverse the effect of direct oral anticoagulants has limited its use in some patients who require rapid reversal of anticoagulation, as those included in the transplant waiting list. Idarucizumab is a recently approved drug to reverse the anticoagulant effect of dabigatran. However, the clinical experience when using this drug is scarce. Herein, we present a clinical case on anticoagulation reversal with idarucizumab to perform heart and lung transplantation in a patient with Eisenmenger syndrome.
与维生素K拮抗剂相比，直接口服抗凝剂已显示出良好的特性。然而，由于缺乏逆转直接口服抗凝剂作用的治疗方法，其在一些需要快速逆转抗凝作用的患者（如移植等待名单中的患者）中的应用受到了限制。依达赛珠单抗是一种最近获批用于逆转达比加群抗凝作用的药物。然而，使用该药物的临床经验很少。在此，我们报告一例使用依达赛珠单抗逆转抗凝作用以对一名艾森曼格综合征患者进行心肺移植的临床病例。
